Related Experiment Videos
Platelets and restenosis
1Division of Interventional Cardiology, Montreal Heart Institute, Montreal, Canada.
Insights
Platelets play a key role in restenosis after percutaneous transluminal coronary angioplasty (PTCA), a major limitation of the procedure. This review explores platelet functions in restenosis and potential drug therapies targeting these effects.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Platelet Biology
Background:
- Restenosis remains a significant challenge following percutaneous transluminal coronary angioplasty (PTCA).
- Key contributors to restenosis include elastic recoil, smooth muscle cell migration and proliferation, and vascular remodeling.
- Current therapeutic options for restenosis are limited.
Purpose of the Study:
- To review the multifaceted role of platelets in the restenotic process after PTCA.
- To examine the efficacy of antiplatelet agents, including glycoprotein IIb/IIIa antagonists, in mitigating restenosis.
- To discuss experimental and clinical findings on drugs targeting platelet activity in restenosis.
Main Methods:
- Literature review of studies investigating platelet involvement in restenosis.
- Analysis of research on antiplatelet therapies and their impact on target vessel revascularization.
- Examination of experimental and human studies on drugs inhibiting platelet effects in restenosis.
Main Results:
- Platelets contribute to thrombosis and abrupt closure post-PTCA, with effects extending into the restenotic phase.
- Glycoprotein IIb/IIIa antagonists show potential in reducing target vessel revascularization, though controversies persist.
- Several drugs have demonstrated promise in preclinical and limited clinical studies for inhibiting platelet-mediated restenosis.
Conclusions:
- Platelets are critically implicated in the pathogenesis of restenosis after PTCA.
- Targeting platelet activity presents a potential therapeutic strategy for managing restenosis.
- Further research is warranted to fully elucidate the role of platelets and optimize antiplatelet therapies for restenosis.
Abstract:
Restenosis is currently the major limitation of percutaneous transluminal coronary angioplasty (PTCA). Factors such as elastic recoil, migration of vascular smooth muscle cells from media to intima, neointimal proliferation and vascular remodeling underly the restenotic process. Presently there is no effective therapy available for restenosis. The role of platelets in the development of thrombosis and abrupt closure after PTCA is well recognized. However, the effects of platelets in PTCA extend well beyond the early phase. Although antiplatelet agents such as glycoprotein IIb/IIIa antagonists have been reported to reduce target vessel revascularization, major unresolved controversies still exist. This report reviews the potential role of platelets in restenosis. Various drugs, successfully tested in experimental studies and in a small number of human studies, that inhibit the effect of platelets on the restenotic process are also reviewed.